Targeting macrophages is a promising therapeutic approach to ovarian cancer and early encouraging work indicates that CSF-1R blockade, anti-B7-H4 scFvs and anti-CCL22 mAbs may generate potent antitumor responses, which is associated with elimination of regulatory T cells. This evidence concerns the gene CD80 and ovarian carcinoma.